Metabolic Signatures and Biomarkers in Schizophrenia

Completed · Phase 1

Conditions studied: Schizophrenia

In brief

We plan to use a metabolomics lipid platform to map biochemical signatures in unmedicated schizophrenic patients prior to and 4 weeks post treatment with the antipsychotic drug aripiprazole and compare that to lipid perturbations induced by risperidone. These drugs have inherently different risk for metabolic adverse effects and patients respond to them differently. Metabolic signatures for the drugs capture significant biochemical information that could explain part of the basis for varied drug response within individuals and will highlight pathways implicated in drug action and in disease pathogenesis possibly enabling new drug design strategies. In addition, we will compare patients to healthy controls at baseline in regard lipid profiles.

Key facts

Study ID

NCT00466310

Run by

Duke University

People needed

71

Starts

2007-02-01

Expected to finish

2011-01-01

Last updated by the study team

2014-07-25

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 18-60 years
• Diagnosis of schizophrenia
• Actively psychotic
• No more than a single dose of antipsychotic in the preceding 2 weeks

You may not qualify if…

• Mental retardation, epilepsy or history of head trauma
• Substance use disorder that explains the majority of the psychopathology
• Pregnant or lactating females

Where it is running

• John Umstead Hospital — Butner, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.